Biotech company Immutep
(ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.
INSIGHT-004 is the 4th arm of the INSIGHT trial is being conducted in collaboration with Merck, Darmstadt, Germany and Pfizer Inc.
The study evaluates the safety, tolerability and recommended Phase II dose of Immutep’s lead immunotherapy product candidate efti-lagimod alpha (“efti” or “IMP321”) when administered in combination with avelu-mab (BAVENCIO®) in 12 patients with advanced solid malignancies.
Shares in Immutep
(ASX:IMM)
